Hospital Angelina Caron, of Campina Grande do Sul, Paraná, is the latest Brazilian hospital to join Clinerion’s network of partner hospitals on its Patient Network Explorer platform. Hospital Angelina Caron has nearly one million patients and specializes in cardiology, ophthalmology, pediatrics and neonatology, gynecology and obstetrics, orthopedics, transplants, obesity and digestive system, oncology, neurology, cardiology, nephrology, vascular and endovascular surgery. The hospital has run 10 international trials per year for the past five years.
Clinerion’s Patient Network Explorer helps partner hospitals be visible to pharmaceutical companies seeking suitable patients and sites for their clinical trials. Leveraging patient medical data, queries based on trial protocols may be sent to partner hospitals to assess the count of eligible patients in their electronic health records. All patient data is de-identified and remains under the control of the hospital and inside its IT infrastructure. However, Clinerion’s patented technology also enables authorized trial staff at the hospital to re-identify the patient for the purpose of trial recruitment, while maintaining strict personal data privacy standards.
“With the Clinerion database system, there will be a great progress in research at our center, facilitating patient selection and increasing our effectiveness. Today, a database and facilitating access to information are fundamental to the evolution of research”, says Dalton B. Precoma MD, PhD, cardiologist of Hospital Angelina Caron.
“We are so pleased that our patient coverage in Brazil is expanding by leaps and bounds,” says Ian Rentsch, CEO of Clinerion. “It shows that the benefits of visibility to pharmaceutical trial sponsors that we offer to hospitals running international clinical trials are well understood and accepted.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.